BeOne Medicines (ONC) Change in Receivables (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Change in Receivables of $75.3 million for Q1 2026, up 136.3% year-over-year from $31.9 million in Q1 2025, and up 3317.95% quarter-over-quarter from -$2.3 million in Q4 2025.
BeOne Medicines (ONC) Change in Receivables (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Change in Receivables for 10 consecutive years, with $75.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 136.3% year-over-year to $75.3 million; the TTM figure through Mar 2026 stood at $208.4 million (down 25.92% YoY), while the FY2025 annual figure was $165.0 million, down 49.93% from the prior year.
- Change in Receivables climbed to $75.3 million in Q1 2026 per ONC's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Change in Receivables topped out at $136.5 million in Q1 2023 and bottomed at -$292.6 million in Q1 2022.
- Historically, Change in Receivables has averaged $26.7 million across 5 years, with a median of $31.9 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 1336.7% — and 2024, when it jumped 2156.77%.
- BeOne Medicines' Change in Receivables stood at -$19.4 million in 2022, then jumped by 330.96% to $44.8 million in 2023, then jumped by 180.61% to $125.7 million in 2024, then slumped by 101.86% to -$2.3 million in 2025, then jumped by 3317.95% to $75.3 million in 2026.
- Business Quant data shows ONC's Change in Receivables at $75.3 million in Q1 2026, -$2.3 million in Q4 2025, and $93.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 117.58 Mn |
| Jun 30, 2026 | 117.58 Mn |
| Mar 31, 2026 | 75.30 Mn |
| Mar 31, 2026 | 75.30 Mn |
| Dec 31, 2025 | -2.34 Mn |
| Dec 31, 2025 | -2.34 Mn |
| Sep 30, 2025 | 93.93 Mn |
| Sep 30, 2025 | 93.93 Mn |
| Jun 30, 2025 | 41.50 Mn |
| Jun 30, 2025 | 41.50 Mn |
| Mar 31, 2025 | 31.87 Mn |
| Mar 31, 2025 | 31.87 Mn |
| Dec 31, 2024 | 125.70 Mn |
| Dec 31, 2024 | 125.70 Mn |
| Sep 30, 2024 | 29.85 Mn |
| Sep 30, 2024 | 29.85 Mn |
| Jun 30, 2024 | 93.87 Mn |
| Jun 30, 2024 | 93.87 Mn |
| Mar 31, 2024 | 80.03 Mn |
| Mar 31, 2024 | 80.03 Mn |